The Bristol-based automation business will be presenting its latest PAT based production optimisation software synTQ V5 to attendees
. As global uptake for the platform goes past the half way point in terms of the world’s top ten pharma production companies adopting it, interest in the solution is accelerating, hence demand for working experience is widespread within the industry. This event is seen as an ideal place to share that knowledge.
The event takes place from 7th – 9th May at the Dorint hotel, Dresden, Germany.
Technical Sales Manager at Optimal, Paul Gillham, will be conducting a presentation on synTQ V5 on the 9th May from 12:20 to 12:40, imparting the benefits of the revolutionary PAT platform.
synTQ is currently in use by over half of the global pharmaceutical manufacturing majors, due to the fact that it enables continuous manufacturing, while also opening the door to the real time release of drugs to market. Uptake of PAT based working structures within the industry is only set to grow, with regulatory bodies such as the FDA now approving continuous manufacturing lines and actively encouraging businesses to engage with the technology.
Suitable for batch and continuous process, in development, test and production – synTQ V5 assesses product quality attributes and process parameters to enable closed loop feedback control of manufacturing processes in real-time. Data is collated and compared to predefined multivariate models, the results of which actively control compounds in production to ensure a finished product that is regulatory compliant. Advantages include an increased speed of manufacture and the elimination of lengthy testing post production, which in many cases reduces time to market for pharmaceuticals from weeks to hours.
Martin Gadsby, Director of Optimal, commented: “We are looking forward to touching base with other PAT users and researchers at the event, where we will be impressing the tangible benefits of synTQ V5 and some of the possible implementation paths available for system integrators. As PAT is a relatively new technology to be implemented in pharmaceutical production – the concepts of which have been around for a while – it is important that decision makers in the industry meet in this manner to share experiences to further develop the capabilities of PAT.”
Other speakers include representatives from Pfizer, Novartis, Vertex, Novo Nordisk, Hermes Pharma, University of Gent and others.
Recent Comments